Platinum/taxane combinations are the most effective regimens for treatment of epithelial ovarian cancer. Response varies between patients, but because the molecular basis for resistance is not defined, patients receive so-called one size fits all therapy. In contrast, elucidation of the molecular events that cause cancer and regulate its progression has led to the development of precision therapies for cancer. One early example is trastuzumab, an anti–human epidermal growth factor receptor 2/neu antibody used to treat breast cancers that overexpress this receptor tyrosine kinase. Immunohistochemical and fluorescence in situ hybridization tests for human epidermal growth factor receptor 2/neu guide its use. Patients lacking overexpression are spared the toxicity and cost of an expensive drug that is unlikely to provide benefit. In the wake of early successes in precision oncology, the US Food and Drug Administration (FDA) promulgated a model in which companion diagnostic (CDx) tests would be developed and approved in parallel with targeted therapies.

中文翻译：

---

卵巢癌的维持性聚（ADP-核糖）聚合酶抑制剂治疗：精确肿瘤学或单一尺寸适合所有人吗？

铂/紫杉烷组合是治疗上皮性卵巢癌的最有效方案。患者之间的反应各不相同，但是由于耐药的分子基础尚未确定，因此患者可以接受一种适合所有治疗的所谓大小疗法。相反，对引起癌症并调节其进展的分子事件的阐明导致了癌症精确疗法的发展。一个早期的例子是曲妥珠单抗，一种抗人表皮生长因子受体2 / neu抗体，用于治疗过度表达该受体酪氨酸激酶的乳腺癌。对人表皮生长因子受体2 / neu的免疫组织化学和荧光原位杂交试验指导其使用。缺乏过度表达的患者可以避免昂贵的药物的毒性和成本，而这种药物不太可能带来益处。